Pharmaceutical composition

a technology of pharmaceutical composition and composition, applied in the field of pharmaceutical composition, can solve problems such as not providing the expected, and achieve the effects of reducing the amount of insulin used, reducing the risk of blood vessel complication and hypoglycemia induction, and excellent blood sugar lowering action

Inactive Publication Date: 2002-07-04
TAKEDA PHARMA CO LTD
View PDF0 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0015] As a result of various studies of medicinal properties such as a diabetic treatment effect, a side effect, etc., the present inventors combined an insulin sensitizer with an anorectic for the first time, and found, for the first time, that such combination unexpectedly provided quite excellent properties as a medicine such as an excellent blood sugar lowering effect, no apparent detection of side effects, etc. Based on this finding, the present inventors have completed the present invention.

Problems solved by technology

However, observance and continuation of the alimentotherapy is accompanied by mental pains of patients, and in many cases does not provide the expected results.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition
  • Pharmaceutical composition
  • Pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

reference example 2

[0197] In the similar manner to Reference Example 1, 140000 tablets having the following composition and each containing 30 mg of pioglitazone were obtained. Composition per tablet (Unit: mg):

2 1) Pioglitazone hydrochloride 33.06 2) Lactose 76.34 3) Carmellose calcium 7.2 4) Hydroxypropylcellulose 3.0 5) Magnesium stearate 0.4 Total: 120.0

reference example 3

[0198] In the similar manner to Reference Example 2, 140000 tablets having the following composition and each containing 45 mg of pioglitazone were obtained. Composition per tablet (Unit: mg):

3 1) Pioglitazone hydrochloride 49.59 2) Lactose 114.51 3) Carmellose calcium 10.8 4) Hydroxypropylcellulose 4.5 5) Magnesium stearate 0.6 Total: 180.0

example 1

[0199] Effects of concomitant administration of pioglitazone hydrochloride and mazindol in noninsulin-dependent diabetic mellitus (NIDDM) patients were studied.

[0200] When pioglitazone hydrochloride (45 mg / day, oral administration) was concomitantly administered to a NIDDM patient [one sample(man); 44 years old; body weight 99.0 kg; fasting blood sugar 242.0 mg / dl; HbA.sub.1c 11.0%] under treatment with mazindol (1.0 mg / day, oral administration) over the period of 8 weeks, fasting blood sugar decreased by 70.0 mg / dl, HbA.sub.1c decreased by 2.00%, and body weight decreased by 1.00 kg.

[0201] When placebo (oral administration) was administered to NIDDM patients [55 samples (20 men and 35 women); 37 to 73 years old (57.9.+-.8.7 (means.+-.standard deviation) years old; body weight 59.8.+-.12.1 (means.+-.standard deviation of 54 samples) kg; fasting blood sugar 180.1.+-.23.0 (means.+-.standard deviation) mg / dl; HbA.sub.1c 8.8.+-.1.3 (means.+-.standard deviation) %] over the period of 12....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

A pharmaceutical composition which comprises an insulin sensitizer in combination with an anorectic, which is useful as an agent for preventing or treating diabetes.

Description

[0001] The present invention relates to a pharmaceutical composition which comprises an insulin sensitizer (insulin resistance-improving agent) in combination with an anorectic. The pharmaceutical composition of the present invention can be used as an agent for preventing or treating diabetes, etc.[0002] Examples of prior art references which relate to an insulin sensitizer or an anorectic are mentioned below.[0003] 1) JP-A H9(1997)-67271 describes "a pharmaceutical composition an insulin sensitivity enhancer in combination with at least one member selected from the group consisting of .alpha.-glucosidase inhibitor, an aldose reductase inhibitor, a biguanide, a statin compound, a squalene synthesis inhibitor, a fibrate compound, a LDL catabolism enhancer and an angiotensin converting enzyme inhibitory".[0004] 2) JP-A H5(1993)-148196 describes that "a pharmaceutical composition comprising 4-[2-(2-hydroxy-2-phenylethylamino)ethoxy]phenyl acetic acid, or its precursor or its pharmaceut...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/421A61K31/425A61K31/426A61K31/44A61K31/4439A61K45/06
CPCA61K31/425A61K31/44A61K45/06A61K31/415A61K2300/00Y10S514/866A61P3/10
Inventor ODAKA, HIROYUKIYAMANE, MASAHIRO
Owner TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products